Formulary guidance and transparency from P&T to point of care


Reality Check on Acute Lymphoblastic Leukemia

Market access for acute lymphoblastic leukemia treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 49% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In April 2020, the FDA cleared an investigational new drug (IND) application for Autolus Therapeutics plc's AUTO1, a CD19-targeting chimeric antigen receptor T-cell therapy for the treatment of adults with acute lymphoblastic leukemia
  • Key Findings: The first-line treatment for many of the variants of ALL is to enroll eligible patients into clinical trials. If this is not done, most medications require prior authorization. To be approved, the patient needs to have had cytogenic testing for the Philadelphia chromosome for initial treatment and documented treatment failures to be placed on more narrow coverage therapies or later-line tyrosine kinase inhibitors

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.